Skip to content

Effect of Oxelidine on early postoperative pain and quality of recovery in patients undergoing thoracoscopic pneumonectomy: a randomized double-blind controlled trial

Effect of Oxelidine on early postoperative pain and quality of recovery in patients undergoing thoracoscopic pneumonectomy: a randomized double-blind controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110618
Enrollment
Unknown
Registered
2025-10-16
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

sufentanil group:sufentanil 2.0µg/kg, diluted to 100 ml with normal saline, loading volume 2 ml, background infusion rate 1ml/h, lockout time 15 min
Oliceridine group:Oliceridine at a dose of 0.6 mg/kg was diluted to 100 ml with normal saline. The loading dose was 2 ml, the background infusion rate was 1 ml/h, and the lockout time was 15 min.
Oliceridine + Sufentanil group:Oliceridine 0.3 mg/kg + Sufentanil 1.0 µg/kg, diluted to 100 ml with normal saline. The loading dose is 2 ml, the background infusion rate is 1 ml/h, and the lockout tim

Sponsors

Tianjin Cancer Hospital Airport Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old, ASA class I-III, BMI18-30kg/m^2; 2. Diagnosis confirmed and requiring unilateral thoracoscopic pneumonectomy (including pulmonary wedge resection, pulmonary segmentectomy, lobectomy and radical resection of lung cancer); 3. Good cardiopulmonary function without surgical contraindications; 4. Informed consent and voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Participation in other clinical trials in recent 3 months; 2. Non-cooperation or withdrawal during the study; 3. American Society of Anesthesiologists (ASA) classification> III; 4. Severe cardiovascular and cerebrovascular diseases; 5. Significant abnormal liver and kidney function; 6. Pulmonary infection; 7. Increased intracranial pressure; 8. Inadequately controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure greater than 180/100 mmHg, 1mmHg=0.133 kPa); 9. History of digestive tract ulcers or bleeding; 10. Tendency to bleed; 11. Hyperthyroidism; 12. Recurrent pulmonary hypertension; 13. Speech disorders or psychiatric disorders; 14. History of long-term opioid use.

Design outcomes

Primary

MeasureTime frame
The incidence of moderate to severe pain (NRS >=4 during coughing) within 48 hours after surgery.;

Secondary

MeasureTime frame
Postoperative recovery status;NRS pain scores at 4 hours after surgery, on postoperative day 1 (POD 1), and on postoperative day 2 (POD 2);Number of postoperative rescue analgesia times;Record the occurrence of adverse reactions in patients.;Effective pressing times of the analgesia pump within 48 hours after surgery;QoR scores of POD1 and POD2;

Countries

China

Contacts

Public ContactZhang Peng

Tianjin Cancer Hospital Airport Hospital

452637954@qq.com+86 138 2068 6080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026